Authors: Flora Mikaeloff, Marco Gelpi, Alejandra Escós, Tianqi Wang, Soham Gupta, Anna Olofsson, Sara Svensson Akusjärvi, Sabrina Schuster, Prajakta Naval, Vikas Sood, Negin Nikouyan, Andreas D. Knudsen, Beate Vestad, Julie Høgh, Johannes R. Hov, Thomas Benfield, Marius Trøseid, Vinay Pawar, Marijana Rucevic, Rui Benfeitas, Ákos Végvári, Liam O'Mahony, Rajkumar Savai, Niklas K. Björkström, Magda Lourda, João Pedro de Magalhães, Siegfried Weiss, Adil Mardinoglu, Mukesh Kumar Varshney, Annika C. Karlsson, Yasir Ahmed Syed, Susanne D. Nielsen, and Ujjwal Neogi
Advanced Science, 27 February 2025
Scientists use Axion BioSystems’ industry-leading Maestro Pro MEA system to explore synaptic function in forebrain organoids in vitro.
Antiretroviral therapy (ART) can successfully control HIV replication and improve immune function for people with HIV (PWH), but prolonged ART contributes to metabolic dysfunction and chronic inflammation, leading to clinical complications and comorbidities. In this study, researchers explored immunometabolic complications and underlying mechanisms in treated PWH.
In addition to multi-omics network analysis and patient stratification, patient-derived forebrain organoids were generated to explore functional effects and validate mechanisms and risk phenotypes in vitro. To assess and confirm deficits in synaptic function of forebrain organoids treated with SPD, an enriched metabolic product identified in at-risk PWH, the team used Axion Biosystems’ noninvasive Maestro Pro multielectrode array (MEA) platform, with findings suggesting a role in immunometabolic disruption. Overall, the authors conclude that, “Identifying the mechanism behind the clinical complications despite successful immune reconstitution and viral suppression opens new avenues for metabolic perturbation targeted therapy for improving the health of PWH.”
